All In Biotech

Drug Trial Radar · NCT07079267

Olpasiran Expanded Access Program

Last checked: Nov 19, 2026Latest source record: Jul 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Jul 23, 2025

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
from 18 years

Summary

As written by the sponsor on the registry.

Expanded access requests for Olpasiran may be considered for adult participants with elevated Lp(a) and atherosclerotic cardiovascular disease (ASCVD). To request access, use Responsible Party contact information provided in this record.

Conditions

No conditions listed.

Interventions

  • OlpasiranDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.